EPISODE · Oct 11, 2022 · 10 MIN
Semaglutide 2.4 mg reduces the 10-year type 2 diabetes risk in people with overweight or obesity - report from EASD2022
from Medical Digest & Congress Report · host Medical Congress News
Professor Timothy Garvey, Director of Diabetes Research Center at University of Alabama presented new data from the STEP trial program at this year EASD Congress in Stockholm. Video: https://congressreport.eu/scientific-contents/interview:semaglutide-24-mg-reduces-10-year-type-2-diabetes-risk-people-overweight-or-obesity
Embed this episode
Ready to play
Semaglutide 2.4 mg reduces the 10-year type 2 diabetes risk in people with overweight or obesity - report from EASD2022
No transcript for this episode yet
Similar Episodes
No similar episodes found.